Antiretroviral Treatments

Share this content:
ANTIRETROVIRAL TREATMENTS
ANTIRETROVIRAL TREATMENTS
Generic Brand Strength Form Usual Dose
CCR5 Co-Receptor Antagonists
maraviroc (MVC) Selzentry 150mg, 300mg tabs Adults: ≥16yrs: Concomitant potent CYP3A inhibitors (eg, PIs [except tipranavir/ritonavir], delavirdine, elvitegravir/ritonavir, ketoconazole, itraconazole, clarithromycin, nefazodone, telithromycin, boceprevir) (with or without a potent CYP3A inducer): 150mg twice daily. Other concomitant drugs, including tipranavir/ritonavir, nevirapine, raltegravir, NRTIs, enfuvirtide: 300mg twice daily. Concomitant potent CYP3A inducers (eg, efavirenz, rifampin, etravirine, carbamazepine, phenobarbital, phenytoin) (without a potent CYP3A inhibitor): 600mg twice daily. Severe renal dysfunction or ESRD (CrCl <30mL/min) (without potent CYP3A inhibitors or inducers): reduce dose from 300mg twice daily to 150mg twice daily if postural hypotension occurs.
Children: <2yrs: not established. ≥2yrs: Concomitant potent CYP3A inhibitors (eg, PIs [except tipranavir/ritonavir], delavirdine, elvitegravir/ritonavir, ketoconazole, itraconazole, clarithromycin, nefazodone, telithromycin, boceprevir) (with or without a potent CYP3A inducer): (10–<20kg): 50mg twice daily; (20–<30kg): 75mg twice daily; (30–<40kg): 100mg twice daily; (≥40kg): 150mg twice daily. Other concomitant drugs, including tipranavir/ritonavir, nevirapine, raltegravir, NRTIs, enfuvirtide: (10–<30kg): not recommended; (30–<40kg or ≥40kg): 300mg twice daily. Concomitant potent CYP3A inducers (eg, efavirenz, rifampin, etravirine, carbamazepine, phenobarbital, phenytoin) (without a potent CYP3A inhibitor): not recommended.
Fusion Inhibitors
enfuvirtide
(ENF, T‑20)
Fuzeon 90mg/mL pwd for SC inj after reconstitution Adults: ≥16yrs: 90mg twice daily via SC inj into upper arm, anterior thigh, or abdomen
Children: <6yrs: not established. ≥6−16yrs: Limited data available; recommended 2mg/kg (max 90mg) twice daily.
HIV-1 Integrase Strand Transfer Inhibitors
dolutegravir Tivicay 10mg, 25mg, 50mg tabs Adults: Treatment-naïve or treatment-experienced INSTI-naïve: 50mg once daily; when concomitant with certain UGT1A or CYP3A inducers: 50mg twice daily. INSTI-experienced with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance: 50mg twice daily.
Children: <30kg or INSTI-experienced with documented or clinically suspected resistance to other INSTIs (raltegravir, elvitegravir): not established. Treatment-naïve or treatment-experienced INSTI-naïve: (30–<40kg): 35mg once daily; (≥40kg): 50mg once daily; when concomitant with certain UGT1A or CYP3A inducers: increase weight-based dose to twice daily.
elvitegravir Vitekta 85mg, 150mg tabs Adults: 85mg once daily regimen: in combination with atazanavir 300mg once daily + ritonavir 100mg once daily; or with lopinavir 400mg twice daily + ritonavir 100mg twice daily.
150mg once daily regimen: in combination with darunavir 600mg twice daily + ritonavir 100mg twice daily; or with fosamprenavir 700mg twice daily + ritonavir 100mg twice daily; or with tipranavir 500mg twice daily + ritonavir 200mg twice daily.
All regimens must be co‑administered with another antiretroviral agent.
Children: Not established.
raltegravir potassium (RAL) Isentress 25mg, 100mg+ chew tabs Adults: 400mg tab twice daily (avoid dosing prior to dialysis). Concomitant rifampin: 800mg twice daily.
Children: <4wks: not established. ≥4wks (≥25kg): one 400mg film-coated tab twice daily. If unable to swallow, can use chew tabs: (25−<28kg): 150mg twice daily; (28−<40kg): 200mg twice daily; ≥40kg: 300mg twice daily. Chew tabs max dose: 300mg twice daily.
400mg tabs
Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
delavirdine mesylate (DLV) Rescriptor 100mg, 200mg tabs Adults: ≥16yrs: 400mg 3 times daily.
Children: <16yrs: not established.
efavirenz (EFV) Sustiva 50mg, 200mg caps Adults and Children: Once daily on an empty stomach, preferably at bedtime. Consider pretreating with antihistamine (for children) or steroid to minimize rash.
<3mos or <3.5kg: not recommended. >3mos: (3.5−<5kg): 100mg; (5−<7.5kg): 150mg; (7.5−<15kg): 200mg; (15−<20kg): 250mg; (20−<25kg): 300mg; (25−<32.5kg): 350mg; (32.5−<40kg): 400mg; (>40kg) and adults: 600mg. Concomitant voriconazole: increase voriconazole maintenance dose to 400mg every 12hrs and decrease efavirenz dose to 300mg once daily using caps.
Concomitant rifampin (≥50kg): increase efavirenz dose to 800mg once daily.
600mg tabs
etravirine (ETR) Intelence 25mg+, 100mg, 200mg tabs Adults and Children: <6yrs or <16kg: not established. Take twice daily after meals.
≥6−<18yrs: (≥16−<20kg): 100mg; (≥20−<25kg): 125mg; (≥25−<30kg): 150mg; (≥30kg) or adults: 200mg.
nevirapine (NVP) Viramune 200mg+ tabs Adults: ≥16yrs: Initially 200mg once daily for 14 days; then 200mg twice daily.
Dialysis: Give additional 200mg after dialysis.
Children: <15days: not recommended. ≥15days: Initially 150mg/m² once daily for 14 days, then increase to 150mg/m² twice daily.
Both: If mild-to-moderate rash occurs during the 14‑day lead‑in period, do not give twice-daily regimen until rash has resolved. Max lead‑in period: 28 days, consider alternative regimen. If severe rash or hepatic event occurs, discontinue permanently. Max 400mg/day. Retitrate if stopped for >7 days.
50mg/
 
5mL
oral susp
Viramune XR 400mg ext-rel tabs Adults: Initially Viramune 200mg once daily for 14 days, then Viramune XR 400mg once daily. If mild-to-moderate rash develops during the 14‑day lead in period, do not start Viramune XR until rash has resolved. Lead‑in period not necessary if patient already on a regimen of immediate-release Viramune twice daily. Max once-daily lead in period: 28 days; consider alternative regimen. If severe rash or hepatic event occurs, discontinue permanently. Retitrate if stopped for >7 days.
Children: <6yrs: not recommended. ≥6–<18yrs: Initially 150mg/m2 Viramune oral susp or IR tabs once daily for 14 days (max 200mg/day); then Viramune XR dose based on BSA: 0.58–0.83m2: 200mg once daily; 0.84–1.16m2: 300mg once daily; ≥1.17m2: 400mg once daily. All: max 400mg/day.
rilpivirine Edurant 25mg tabs Adults and Children: <12yrs: not recommended. ≥12yrs (≥35kg): 25mg once daily with a meal.
Concomitant rifabutin: 50mg once daily; decrease to 25mg once daily when rifabutin is stopped.
Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
abacavir sulfate (ABC) Ziagen 300mg tabs Adults: >16yrs: 300mg twice daily or 600mg once daily. Mild hepatic impairment: 200mg twice daily.
Children: <3mos: not established. ≥3mos (oral soln): 8mg/kg twice daily or 16mg/kg once daily; max 600mg daily. If able to swallow tabs: 14−<20kg: 300mg once daily or 150mg twice daily; ≥20−<25kg: 450mg once daily or 150mg in the AM and 300mg in the PM; ≥25kg: use Adult dose.
20mg/mL oral soln1
abacavir sulfate (ABC)/
lamivudine (3TC)
Epzicom ABC/
 
3TC:
600mg/
 
300mg
tabs Adults: >18yrs: 1 tab daily. Hepatic or renal impairment (CrCl <50mL/min): not recommended.
Children: ≤18yrs: not recommended.
abacavir sulfate (ABC)/
lamivudine (3TC)/
zidovudine (ZDV)
Trizivir ABC/
 
3TC/
  
ZDV:
300mg/
 
150mg/
  300mg
tabs Adults: <40kg: not recommended. ≥40kg: 1 tab twice daily.
Children: Not recommended.
didanosine (ddl) Videx EC 125mg, 200mg, 250mg, 400mg e‑c del‑rel caps Adults and Children: Take once daily on an empty stomach. <20kg: use oral soln. 20−<25kg: 200mg. 25−<60kg: 250mg. ≥60kg: 400mg.
Renal impairment (CrCl 30−59mL/min): <60kg: 125mg. ≥60kg: 200mg. CrCl 10−29mL/min: 125mg. CrCl <10mL/min or dialysis: <60kg: Use oral soln; ≥60kg: 125mg.
Videx Pediatric Pwd for Oral Soln 4g pediatric pwd for oral soln after reconstitution Adults: Take on an empty stomach. <60kg: 125mg twice daily or 250mg once daily. ≥60kg: 200mg twice daily or 400mg once daily.
Renal impairment (CrCl 30−59mL/min): <60kg: 150mg once daily or 75mg twice daily; ≥60kg: 200mg once daily or 100mg twice daily; CrCl 10−29mL/min: <60kg: 100mg once daily; ≥60kg: 150mg once daily; CrCl <10mL/min or dialysis: <60kg: 75mg once daily; ≥60kg: 100mg once daily.
Children: <2wks: not recommended. 2wks−8mos: 100mg/m² twice daily. ≥8mos: 120mg/m² twice daily.
Renal impairment: Consider reducing dose and/or increasing dosing interval. See full labeling.
emtricitabine (FTC) Emtriva 200mg caps Adults: ≥18yrs: 200mg once daily. Renal impairment (CrCl 30−49mL/min): 200mg every 48hrs; (CrCl 15−29mL/min): 200mg every 72hrs; (CrCl <15mL/min or dialysis): 200mg every 96hrs.
Children: <3mos: not recommended. 3mos−17yrs: ≤33kg: use soln form. >33kg: 200mg once daily. Renal impairment: Reduce dose or prolong dosing interval.
10mg/mL oral soln Adults: ≥18yrs: 240mg once daily. Renal impairment: (CrCl 30−49mL/min): 120mg once daily; (CrCl 15−29mL/min): 80mg once daily; (CrCl <15mL/min): 60mg once daily.
Children: <3mos: 3mg/kg once daily. 3mos−17yrs: 6mg/kg once daily; max 240mg/day. >33kg: May use cap form. Renal impairment: Reduce dose or prolong dosing interval.
emtricitabine (FTC)/
tenofovir disoproxil fumarate (TDF)
Truvada 100mg/150mg, 133mg/200mg,
167mg/250mg, 200mg/300mg
tabs Adults: ≥35kg: 200mg/300mg once daily. Renal impairment: CrCl 30–49mL/min: 200mg/300mg every 48hrs; CrCl <30mL/min, hemodialysis: not recommended.
Children: <17kg: not established. 17–<22kg: 100mg/150mg once daily. 22–<28kg: 133mg/200mg once daily. 28–<35kg: 167mg/250mg once daily. ≥35kg: 200mg/300mg once daily.
lamivudine (3TC) Epivir 150mg+, 300mg tabs Adults: CrCl ≥50mL/min: 300mg once daily or 150mg twice daily; CrCl 30−49mL/min: 150mg once daily; CrCl 15−29mL/min: 150mg for 1st dose then 100mg once daily; CrCl 5−14mL/min: 150mg for 1st dose then 50mg once daily; CrCl <5mL/min: 50mg for 1st dose then 25mg once daily.
Children: <3mos: not established. ≥3mos (oral soln): 4mg/kg twice daily or 8mg/kg once daily; max 300mg/day. Tabs: 14−<20kg: 150mg once daily or 75mg twice daily; ≥20−<25kg: 225mg once daily or 75mg in the AM and 150mg in the PM; ≥25kg: 300mg once daily or 150mg twice daily. Renal impairment: reduce dose or prolong dosing interval.
10mg/mL oral soln
lamivudine (3TC)/ zidovudine (ZDV) Combivir 3TC/
 
ZDV:
150mg/
 
300mg
tabs Adults: 1 tab twice daily. Hepatic or renal impairment (CrCl <50mL/min): not recommended.
Children: Not recommended.
stavudine (d4T) Zerit 15mg, 20mg, 30mg, 40mg caps Adults: ≥60kg: 40mg every 12hrs; <60kg: 30mg every 12hrs.
Renal impairment: ≥60kg (CrCl 26−50mL/min): 20mg every 12hrs; (CrCl 10−25mL/min), dialysis: 20mg every 24hrs. <60kg (CrCl 26−50mL/min): 15mg every 12hrs; (CrCl 10−25mL/min), dialysis: 15mg every 24hrs.
Children: ≤13 days: 0.5mg/kg every 12hrs. ≥14 days: (<30kg): 1mg/kg every 12hrs. ≥30kg: as adult.
Renal impairment: Reduce dose or increase dosing interval.
1mg/mL pwd for oral soln after reconsti-
tution
tenofovir disoproxil fumarate (TDF) Viread 150mg, 200mg, 250mg, 300mg tabs Adults: ≥12yrs (≥35kg): 300mg once daily. Renal impairment: CrCl 30–49mL/min: 300mg every 48hrs; CrCl 10–29mL/min: 300mg every 72–96hrs; hemodialysis: 300mg every 7 days or after a total of 12hrs of dialysis; CrCl <10mL/min: not recommended.
40mg/g oral pwd Children: <2yrs: not established.
≥2yrs: 8mg/kg once daily; max 300mg/day. ≥17kg: may use tabs if able to swallow. 17–<22kg: 150mg once daily. 22–<28kg: 200mg once daily. 28–<35kg: 250mg once daily. ≥35kg: 300mg once daily. See full labeling for additional dosing based on body wt.
zidovudine (ZDV) Retrovir 100mg caps Adults: ≥18yrs: 600mg daily in divided doses. End‑stage renal disease on dialysis: 100mg every 6−8hrs. Vertical transmission, severe anemia and/or neutropenia: See full labeling.
300mg tabs Children: <6wks and/or for vertical transmission: See full labeling.
6wks−<18yrs: (4−<9kg): 24mg/kg/day (12mg/kg twice daily or 8mg/kg 3 times daily);
(≥9−<30kg): 18mg/kg/day (9mg/kg twice daily or 6mg/kg 3 times daily);
(≥30kg): 600mg/day (300mg twice daily or 200mg 3 times daily).
Alternative dosing based on BSA: 240mg/m² twice daily or 160mg/m² 3 times daily.
50mg/
 
5mL
syrup
10mg/mL soln for IV inj after dilution Adults: Give by IV infusion over 1hr; use only until oral therapy can be given. 1mg/kg 5−6 times daily. End‑stage renal disease on dialysis: 1mg/kg every 6−8hrs. Vertical transmission, severe anemia and/or neutropenia: See full labeling.
Children: Vertical transmission: See full labeling.
Pharmacokinetic Enhancer
cobicistat Tybost 150mg tabs Adults: Must be co‑administered at same time as atazanavir or darunavir.
≥18yrs: 150mg once daily with atazanavir 300mg once daily (if treatment-naive or experienced) or with darunavir 800mg once daily (if treatment-naive or experienced with no darunavir resistance associated substitutions).
Children: <18yrs: not established.
Protease Inhibitors (PIs)
atazanavir sulfate (ATV) Reyataz 150mg, 200mg, 300mg caps Adults: Take with food.
Treatment-naive: atazanavir 300mg + ritonavir 100mg once daily;
atazanavir 400mg once daily if unable to tolerate ritonavir; concomitant efavirenz: atazanavir 400mg + ritonavir 100mg once daily + efavirenz 600mg at bedtime (on an empty stomach);
ESRD with hemodialysis: atazanavir 300mg + ritonavir 100mg; hepatic impairment: (mild): 400mg once daily; (moderate): 300mg once daily; (severe): not recommended.
Treatment-experienced: atazanavir 300mg + ritonavir 100mg once daily;
concomitant H2‑blocker and tenofovir: atazanavir 400mg + ritonavir 100mg once daily.
Concomitant tenofovir: atazanavir 300mg + tenofovir 300mg + ritonavir 100mg once daily.
Pregnancy: atazanavir 300mg + ritonavir 100mg once daily; concomitant H2‑blocker or tenofovir (2nd or 3rd trimester): atazanavir 400mg + ritonavir 100mg. See full labeling.
Children: <6yrs: not recommended. Take with food. Take once daily.
6−18yrs: 15−<20kg: atazanavir 150mg + ritonavir 100mg; 20−<40kg: atazanavir 200mg + ritonavir 100mg; ≥40kg: atazanavir 300mg + ritonavir 100mg.
Treatment-naive: ≥13yrs and ≥40kg who are unable to tolerate ritonavir: atazanavir 400mg once daily.
Patients ≥13yrs and ≥40kg receiving concomitant tenofovir, H2‑blockers, or PPIs: take atazanavir with ritonavir. See full labeling.
50mg oral pwd3
darunavir ethanolate (DRV) Prezista 75mg, 150mg, 600mg, 800mg tabs Adults: ≥18yrs: Treatment-naive or treatment-experienced with no darunavir resistance associated substitutions: darunavir 800mg + ritonavir 100mg once daily. Treatment-experienced with at least one darunavir resistance associated substitution or with no baseline resistance information: darunavir 600mg + ritonavir 100mg twice daily. Pregnancy: darunavir 600mg + ritonavir 100mg twice daily; may consider darunavir 800mg + ritonavir 100mg once daily only if stable on dose prior to pregnancy and virologically suppressed (HIV-1 RNA <50copies/mL).
Children: <3yrs: not recommended. Treatment-naive or treatment-experienced with no darunavir resistance associated substitutions: ≥3yrs to <18yrs: ≥10kg–<11kg: darunavir 350mg + ritonavir 64mg once daily; ≥11kg–<12kg: darunavir 385mg + ritonavir 64mg once daily; ≥12kg–<13kg: darunavir 420mg + ritonavir 80mg once daily; ≥13kg–<14kg: darunavir 455mg + ritonavir 80mg once daily; ≥14kg–<15kg: darunavir 490mg + ritonavir 96mg once daily; ≥15–<30kg: darunavir 600mg + ritonavir 100mg once daily; ≥30kg–<40kg: darunavir 675mg + ritonavir 100mg once daily; ≥40kg: darunavir 800mg + ritonavir 100mg once daily. Treatment-experienced with at least one darunavir resistance associated substitution: ≥3yrs to <18yrs: ≥10kg–<11kg: darunavir 200mg + ritonavir 32mg twice daily; ≥11kg–<12kg: darunavir 220mg + ritonavir 32mg twice daily; ≥12kg–<13kg: darunavir 240mg + ritonavir 40mg twice daily; ≥13kg–<14kg: darunavir 260mg + ritonavir 40mg twice daily; ≥14kg–<15kg: darunavir 280mg + ritonavir 48mg twice daily; ≥15–<30kg: darunavir 375mg + ritonavir 48 mg twice daily; ≥30kg–<40kg: darunavir 450mg + ritonavir 60mg twice daily; ≥40kg: darunavir 600mg + ritonavir 100mg twice daily.
See full labeling for complete weight based dosing.
Both: Take with food.
Severe hepatic impairment: not recommended.
100mg/
 
mL
oral susp
fosampre-
navir calcium (FOS‑APV)
Lexiva 700mg tabs Adults: Oral susp: take without food.
Therapy-naive: 1.4g twice daily; or fosamprenavir 1.4g + ritonavir 200mg once daily; or fosamprenavir 1.4g + ritonavir 100mg once daily; or fosamprenavir 700mg + ritonavir 100mg twice daily.
PI‑experienced: fosamprenavir 700mg + ritonavir 100mg twice daily.
Hepatic dysfunction: See full labeling.
Children: PI‑naive (<4wks) or PI‑experienced (<6mos): not recommended.
Oral susp: Take twice daily with food.
PI‑naive (≥4wks−18yrs) or PI‑experienced (≥6mos): <11kg: fosamprenavir 45mg/kg + ritonavir 7mg/kg; 11−<15kg: fosamprenavir 30mg/kg + ritonavir 3mg/kg; 15−<20kg: fosamprenavir 23mg/kg + ritonavir 3mg/kg; ≥20kg: fosamprenavir 18mg/kg + ritonavir 3mg/kg. PI‑naive (≥2yrs): fosamprenavir 30mg/kg.
Both: If emesis occurs within 30min after dosing, re‑dose. Do not exceed adult dose. See full labeling.
50mg/mL oral susp
indinavir sulfate (IDV) Crixivan 200mg, 400mg caps Adults: Take with water on an empty stomach or with a light meal. 800mg every 8hrs.
Concomitant rifabutin: 1g every 8hrs and reduce rifabutin dose by ½.
Concomitant ketoconazole, itraconazole, delavirdine, or hepatic insufficiency: 600mg every 8hrs.
Children: Not established. 3−18yrs: 500mg/m² every 8hrs has been used; see full labeling.
lopinavir (LPV)/ ritonavir (RTV) Kaletra LPV/
 
RTV: 100mg/
 
25mg, 200mg/
 
50mg
tabs Adults: Oral soln: take with food. ≥18yrs: <3 lopinavir resistance-associated substitutions: 400/100mg twice daily or 800/200mg once daily. ≥3 lopinavir resistance-associated substitutions or concomitant carbamazepine, phenobarbital, phenytoin, efavirenz, nevirapine, nelfinavir, or if pregnant (avoid oral soln): once-daily dosing not recommended. Concomitant efavirenz, nevirapine, or nelfinavir: 500/125mg (two 200/50mg tabs + one 100/25mg tab) or 520/130mg (6.5mL) twice daily.
Children: <42wks postmenstrual age or <14 days postnatal: not recommended.
14days–6mos: 16/4mg/kg or 300/75mg/m2 twice daily. Do not administer with efavirenz, nevirapine, or nelfinavir. >6mos–<18yrs: 230/57.5mg/m2 twice daily or, if <15kg: 12/3mg/kg twice daily;
≥15–40kg: 10/2.5mg/kg twice daily;
>40kg: max 400/100mg twice daily.
Concomitant efavirenz, nevirapine, or nelfinavir: >6mos–<18yrs: 300/75mg/m2 twice daily, or if <15kg: 13/3.25mg/kg twice daily; ≥15–45kg: 11/2.75mg/kg twice daily; >45kg: max oral soln: 520/130mg (6.5mL) twice daily; or max tabs: 500/125mg twice daily. See full labeling.
LPV/
 
RTV: 80mg/
 
20mg per mL
oral soln2,5
nelfinavir mesylate (NFV) Viracept 250mg, 625mg tabs Adults and Children: Take with food.
<2yrs: not recommended.
2−13yrs: 45−55mg/kg twice daily or 25−35mg/kg 3 times daily; max 2.5g/day. >13yrs: 1.25g twice daily or 750mg 3 times daily. Reduce concomitant rifabutin dose by ½ and give nelfinavir 1.25g twice daily.
50mg/g oral pwd3
ritonavir (RTV) Norvir 100mg tabs, soft gel caps2,5 Adults: Take with meals. Initially at least 300mg twice daily, increase every 2−3 days by 100mg twice daily to 600mg twice daily.
Concomitant other Pls (eg, atazanavir, darunavir, fosamprenavir, saquinavir, tipranavir): Reduce ritonavir dose. See full labeling.
80mg/mL oral soln2 Children: <1mo or before postmenstrual age <44wks: not recommended. >1mo: Initially 250mg/m² twice daily; increase every 2−3 days by 50mg/m² twice daily to 350−400mg/m² twice daily; max 600mg twice daily.
saquinavir mesylate (SQV) Invirase 500mg tabs Adults: Take within 2hrs after a meal.
≥16yrs: saquinavir 1g twice daily + ritonavir 100mg twice daily (taken at same time).
Treatment-naive or switching from a delavirdine- or rilpivirine-containing regimen: initially saquinavir 500mg twice daily + ritonavir 100mg twice daily for 7 days, then increase to saquinavir 1g twice daily + ritonavir 100mg twice daily.
Children: <16yrs: not recommended.
200mg hard gel caps
tipranavir (TPV) Aptivus 250mg soft gel caps2 Adults: Tipranavir 500mg + ritonavir 200mg twice daily.
Children: <2yrs: not recommended.
Use oral soln if unable to swallow caps.
2−18yrs: tipranavir 14mg/kg + ritonavir 6mg/kg or (375mg/m² + ritonavir 150mg/m²) twice daily; max tipranavir 500mg + ritonavir 200mg twice daily.
Intolerance or toxicity (if virus not resistant to multiple PIs): may reduce dose to tipranavir 12mg/kg + ritonavir 5mg/kg or (290mg/m² + ritonavir 115mg/m²) twice daily.
100mg/
 
mL
oral soln4
Multiclass Fixed-Dose Combination
abacavir/
dolutegravir/
lamivudine
Triumeq 600mg/
 
50mg/
  300mg
tabs Adults: 1 tab daily. Concomitant efavirenz, fosamprenavir/ritonavir, tipranavir/ritonavir, rifampin, carbamazepine: give additional dolutegravir 50mg separated by 12hrs from Triumeq.
Children: Not established.
atazanavir/
cobicistat
Evotaz 300mg/
 
150mg
tabs Adults: 1 tab daily.
Children: <18yrs: not established.
darunavir/
cobicistat
Prezcobix 800mg/
 
150mg
tabs Adults: 1 tab daily.
Children: <18yrs: not established.
efavirenz (EVF)/
emtricitabine (FTC)/
tenofovir disoproxil fumarate (TDF)
Atripla 600mg/
 
200mg/
  300mg
tabs Adults: ≥12yrs and ≥40kg: 1 tab once daily preferably at bedtime. Concomitant rifampin (≥50kg): Give additional 200mg/day of efavirenz.
Children: <12yrs: not recommended.
emtricitabine (FTC)/
rilpivirine/
tenofovir alafenamide (TAF)
Odefsey 200mg/
 
25mg/
  25mg
tabs Adults and Children: <12yrs (<35kg): not established. ≥12yrs (≥35kg): 1 tab once daily with food.
Severe renal impairment (CrCl <30mL/min): not recommended.
emtricitabine (FTC)/
rilpivirine/
tenofovir disoproxil fumarate (TDF)
Complera 200mg/
 
25mg/
  300mg
tabs Adults: ≥12yrs (and ≥35kg): 1 tab once daily with a meal. Renal impairment (CrCl<50mL/min): not recommended. Concomitant rifabutin: take additional rilpivirine 25mg once daily.
Children: <12yrs or <35kg: not established.
emtricitabine (FTC)/
tenofovir alafenamide (TAF)
Descovy 200mg/
 
25mg
tabs Adults and Children: <12yrs (<35kg): not established. ≥12yrs (≥35kg): 1 tab once daily.
Severe renal impairment (CrCl <30mL/min): not recommended.
elvitegravir/cobicistat/
emtricitabine (FTC)/
tenofovir alafenamide (TAF)
Genvoya 150mg/
 
150mg/
  200mg/10mg
tabs Adults and Children: <12yrs: not established. ≥12yrs and ≥35kg: 1 tab once daily with food.
Severe hepatic or renal impairment (CrCl <30mL/min): not recommended.
elvitegravir/
cobicistat/
emtricitabine
 (FTC)/
tenofovir disoproxil fumarate (TDF)
Stribild 150mg/
 
150mg/
  200mg/
   
300mg
tabs Adults and Children: <12yrs or <35kg: not established. ≥12yrs (≥35kg): 1 tab once daily with food. Renal impairment (CrCl <70mL/min): not recommended; discontinue if CrCl declines to <50mL/min during therapy; also in children: no data available. Severe hepatic impairment: not recommended.
NOTES

Key: + = scored; PI = protease inhibitor

1Contains parabens, propylene glycol; 2Contains alcohol; 3Contains phenylalanine; 4Contains Vit. E 116 IU/mL; 5Keep in refrigerator

(Rev. 5/2017)

You must be a registered member of Infectious Disease Advisor to post a comment.

Sign Up for Free e-newsletters